Skip to content

Clinical study of Jinshuibao Capsule to improve ivF-ET pregnancy outcome in infertile patients with renal deficiency and ovarian reserve dysfunction

Clinical study of Jinshuibao Capsule to improve ivF-ET pregnancy outcome in infertile patients with renal deficiency and ovarian reserve dysfunction

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036736
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility associated with ovarian dysfunction

Interventions

Sponsors

China Welfare Association International Peace Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) The age range is 18 to 39; (2) It conforms to the diagnostic criteria of western medicine and Chinese medicine at the same time; (3) All planned to perform IVF-ET transplantation in the Reproductive Center of The International Peace Maternal and Child Health Center of China Welfare Association (ADOPT GNRH-A ultra-long natural cycle freeze-thawed embryo transplantation D3); (4) those who have not taken medication or have taken medication but have stopped taking medication for more than 3 months; (5) Volunteer to participate in this clinical study and sign the relevant informed consent.

Exclusion criteria

Exclusion criteria: (1) Any contraindications in accordance with IVF-ET and its derived technologies shall be excluded; (2) Those who have used hormone drugs in recent 3 months; (3) Infertility caused by ovulation disorders, immune factors and chromosomal abnormalities; (4) Abnormal analysis of male semen; (5) Persons with a history of severe drug allergy; (6) Patients with breast or other reproductive organ diseases, such as multiple uterine fibroids, polycystic ovary syndrome, endometriosis, malformation of reproductive organs or physiological defects, or those with serious medical diseases; (7) People who are allergic to multiple drugs or have known allergies to the components of this drug; (8) Participating in other clinical trial projects.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;

Secondary

MeasureTime frame
clinical symptoms;laboratory index;

Countries

China

Contacts

Public ContactJin Yu

China Welfare Association International Peace Maternal and Child Health Hospital

395005545@163.com+86 15821627980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026